Roivant Sciences Ltd.
ROIVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRoivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Valued at $24.82B, ROIV is a large-cap name in its sector. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Market Cap
$24.82B
Beta
1.11
P/E (TTM)
—
P/E (Fwd)
-22.13
EPS (TTM)
$-0.55
EPS (Fwd)
$-1.56
ROE
-7.6%
ROA
-14.3%
Cash
$4.29B
Total Debt
$107.4M
Free CF
-$1.09B
52W Change
201.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $4.29B in cash comfortably exceeding the $107.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.09B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -7.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $31.5M (2023) to $8.3M (2026), a 74% decline worth watching.
With cash comfortably exceeding debt, ROIV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Roivant Sciences Ltd. and its sector.